Design of Bactericidal Peptides Against Escherichia coli O157:H7, Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus

Cruz, Jenniffer; Rondón-Villarreal, Paola; Torres, Rodrigo; Urquiza, Mauricio; Guzmán, Fanny; Álvarez, Claudio; Abengózar, María Ángeles; Sierra, Daniel A.; Rivas, Luís; Fernández-Lafuente, Roberto; Ortíz, Claudia

doi:10.2174/1573406414666180508120024

Cited by 7 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For instance, GIBIM-P5S9K (G17), a new antimicrobial peptide, designed through a genetic algorithm optimization strategy, has showed a wide range of activity against MRSA, E. coli O157:H7 and P. aeruginosa. In addition, previous studies have shown that a nanoencapsulated preparation of G17 displays both low erythrocyte hemolysis and cytotoxicity, and it is stable in human sera [17]. In this work, GAM019 (G19), an analogue of the G17 peptide was synthesized by solid-phase chemistry and encapsulated in PLGA at different peptide/biopolymer ratios in order to obtain the best physicochemical properties of surface charge, size, encapsulation efficiency and also improve its antimicrobial activity against MRSA and E. coli O157:H7.…”

Section: Introductionmentioning

confidence: 99%

Potent and Specific Antibacterial Activity against Escherichia coli O157:H7 and Methicillin Resistant Staphylococcus aureus (MRSA) of G17 and G19 Peptides Encapsulated into Poly-Lactic-Co-Glycolic Acid (PLGA) Nanoparticles

et al. 2020

Self Cite

View full text Add to dashboard Cite

Antimicrobial peptides constitute an excellent alternative against conventional antibiotics because of their potent antimicrobial spectrum, unspecific action mechanism and low capacity to produce antibiotic resistance. However, a potential use of these biological molecules as therapeutic agents is threatened by their low stability and susceptibility to proteases. In order to overcome these limitations, encapsulation in biocompatible polymers as poly-lactic-glycolic-acid (PLGA) is a promising alternative for increasing their stability and bioavailability. In this work, the effect of new synthetic antimicrobial peptides GIBIM-P5S9K (G17) and GAM019 (G19) encapsulated on PLGA and acting against methicillin resistant Staphylococus aureus (MRSA) and Escherichia coli O157:H7 was studied. PLGA encapsulation allowed us to load around 7 µg AMPs/mg PLGA with an efficiency of 90.5%, capsule sizes around 290 nm and positive charges. Encapsulation improved antimicrobial activity, decreasing MIC50 from 1.5 to 0.2 (G17NP) and 0.7 (G19NP) µM against MRSA, and from 12.5 to 3.13 µM for E. coli O157:H7. Peptide loaded nanoparticles could be a bacteriostatic drug with potential application to treat these bacterial E. coli O157:H7 and MRSA infections, with a slow and gradual release.

show abstract

Section: Introductionmentioning

confidence: 99%

Potent and Specific Antibacterial Activity against Escherichia coli O157:H7 and Methicillin Resistant Staphylococcus aureus (MRSA) of G17 and G19 Peptides Encapsulated into Poly-Lactic-Co-Glycolic Acid (PLGA) Nanoparticles

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Antimicrobial peptides (AMP) have a low propensity for bacteria resistance [71,72]. The research group of Rondón-Villarreal [11] developed an AMP library using the CAMP R3 [73] database, and genetic algorithms. The peptide library was designed with specific physicochemical properties (charge, hydrophobicity, isoelectric point, and stability index) and tested against E. coli, Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus.…”

Section: General Opportunitiesmentioning

confidence: 99%

“…The speakers (8 researchers working in a Latin American Country or from Latin American origin) have a broad perspective since they work in academia, industry (large pharmaceutical companies or new start-ups), public research institutions or non-for-profit organizations. Machine learning in virtual screening and peptide's design [11] Fabien Plisson…”

Section: Introductionmentioning

confidence: 99%

Chemoinformatics and Artificial Intelligence Colloquium: Progress and Challenges to Develop Bioactive Compounds

Bajorath

Chávez-Hernández

Duran‐Frigola³

et al. 2022

Preprint

View full text Add to dashboard Cite

We report the main conclusions of the first Chemoinformatics and Artificial Intelligence Colloquium, Mexico City (virtual), June 15-17, 2022. Fifteen lectures were presented during a virtual and public event with speakers from industry, academia, and non-for-profit organizations. 1,290 participants, including students and academics from more than 60 countries, had registered. During the meeting, applications, challenges, and opportunities in drug discovery, de novo drug design, ADME-Tox (Absorption, Distribution, Metabolism, Excretion and Toxicity) property predictions, organic chemistry and peptides, and antibiotic resistance were discussed. The program, along with the recordings of all sessions, is freely available at https://www.difacquim.com/english/events/2022-colloquium/

show abstract

“…Thus, in recent years, many researchers have used AMPs instead of traditional antibiotics to modify skin dressing materials and apply them to skin injury repair ( Gomez-Sequeda et al, 2020 ). For example, based on optimizing the physicochemical properties of the peptide, Jenniffer and their team made reasonable modifications to its sequence and designed a new antibacterial peptide (P5S9K) ( Cruz et al, 2018 ). The results showed that the AMPs adopted a helical structure in a simulated cell membrane environment and could pass through the cell membrane of pathogenic bacteria in a dose-dependent manner, thus reaching an antibacterial effect.…”

Section: Introductionmentioning

confidence: 99%

Acceleration of Healing in Full-Thickness Wound by Chitosan-Binding bFGF and Antimicrobial Peptide Modification Chitosan Membrane

Hou

Wang

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Skin wound healing is an important clinical challenge, and the main treatment points are accelerating epidermal regeneration and preventing infection. Therefore, it is necessary to develop a wound dressing that can simultaneously cure bacterial infections and accelerate wound healing. Here, we report a multifunctional composite wound dressing loaded with chitosan (CS)-binding bFGF (CSBD-bFGF) and antimicrobial peptides (P5S9K). First, CS was used as the dressing matrix material, and P5S9K was encapsulated in CS. Then, CSBD-bFGF was designed by combining recombinant DNA technology and tyrosinase treatment and modified on the dressing material surface. The results show that the binding ability of CSBD-bFGF and CS was significantly improved compared with that of commercial bFGF, and CSBD-bFGF could be controllably released from the CS dressing. More importantly, the prepared dressing material showed excellent antibacterial activity in vivo and in vitro and could effectively inhibit the growth of E. coli and S. aureus. Using NIH3T3 cells as cellular models, the results showed that the CSBD-bFGF@CS/P5S9K composite dressing was a friendly material for cell growth. After cells were seeded on the composite dressing surface, collagen-1 (COL-1) and vascular endothelial growth factor (VEGF) genes expression in cells were significantly upregulated. Finally, the full-thickness wound of the rat dorsal model was applied to analyse the tissue repair ability of the composite dressing. The results showed that the composite dressing containing CSBD-bFGF and P5S9K had the strongest ability to repair skin wounds. Therefore, the CSBD-bFGF@CS/P5S9K composite dressing has good antibacterial and accelerated wound healing abilities and has good application prospects in the treatment of skin wounds.

show abstract

Design of Bactericidal Peptides Against Escherichia coli O157:H7, Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus

Cited by 7 publications

References 0 publications

Potent and Specific Antibacterial Activity against Escherichia coli O157:H7 and Methicillin Resistant Staphylococcus aureus (MRSA) of G17 and G19 Peptides Encapsulated into Poly-Lactic-Co-Glycolic Acid (PLGA) Nanoparticles

Potent and Specific Antibacterial Activity against Escherichia coli O157:H7 and Methicillin Resistant Staphylococcus aureus (MRSA) of G17 and G19 Peptides Encapsulated into Poly-Lactic-Co-Glycolic Acid (PLGA) Nanoparticles

Chemoinformatics and Artificial Intelligence Colloquium: Progress and Challenges to Develop Bioactive Compounds

Acceleration of Healing in Full-Thickness Wound by Chitosan-Binding bFGF and Antimicrobial Peptide Modification Chitosan Membrane

Contact Info

Product

Resources

About